IRIS
ALTOMONTE, MARESA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 979
EU - Europa 914
AS - Asia 175
OC - Oceania 1
Totale 2.069
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 975
IE - Irlanda 234
GB - Regno Unito 185
DE - Germania 126
CN - Cina 104
IT - Italia 99
RU - Federazione Russa 74
SE - Svezia 69
UA - Ucraina 45
FR - Francia 41
VN - Vietnam 38
ES - Italia 17
SG - Singapore 17
FI - Finlandia 14
KR - Corea 9
IN - India 4
AZ - Azerbaigian 2
CH - Svizzera 2
IM - Isola di Man 2
AU - Australia 1
BG - Bulgaria 1
CA - Canada 1
DO - Repubblica Dominicana 1
EE - Estonia 1
HR - Croazia 1
JP - Giappone 1
LV - Lettonia 1
MX - Messico 1
NL - Olanda 1
PA - Panama 1
PL - Polonia 1
Totale 2.069
Salva come PNG Salva come JPEG
Città #
Dublin 233
Fairfield 166
Southend 166
Ashburn 98
Houston 78
Woodbridge 78
Cambridge 69
Wilmington 69
Seattle 51
Chandler 49
Siena 47
Jacksonville 43
Dong Ket 38
Princeton 37
Ann Arbor 32
Dearborn 31
Beijing 23
New York 19
Málaga 17
San Mateo 17
Shanghai 16
Nanjing 11
San Diego 11
Helsinki 10
London 8
Singapore 8
Moscow 7
Nanchang 6
Yongsan-gu 6
San Giovanni Valdarno 5
Venezia 5
Boardman 4
Hefei 4
Jinan 4
Düsseldorf 3
Empoli 3
Florence 3
Kunming 3
Palermo 3
Rome 3
Schwielowsee 3
Tianjin 3
Altamura 2
Asciano 2
Baku 2
Carmignano 2
Changsha 2
Chiusdino 2
Delhi 2
Falls Church 2
Guangzhou 2
Hangzhou 2
Islington 2
Kilburn 2
Livorno 2
Newark 2
Ningbo 2
Phoenix 2
Saha-gu 2
San Francisco 2
Zurich 2
Acton 1
Amsterdam 1
Arezzo 1
Canberra 1
Changchun 1
Fremont 1
Fuzhou 1
Guiyang 1
Hebei 1
Hounslow 1
Hyderabad 1
Jiaxing 1
Lanzhou 1
Lappeenranta 1
Lucca 1
Mexico City 1
Nanning 1
Norwalk 1
Redmond 1
Reston 1
Richmond 1
Riga 1
Roseto Degli Abruzzi 1
Santo Domingo Este 1
Shaoxing 1
Shenyang 1
Shinjuku 1
Sofia 1
Stockholm 1
Tallinn 1
Toronto 1
Vicenza 1
Wandsworth 1
Wenzhou 1
Xian 1
Zagreb 1
Totale 1.564
Salva come PNG Salva come JPEG
Nome #
Ipilimumab experience in heavily pretreated patients with melanoma in an expanded access program at the University Hospital of Siena (Italy) 210
Long-term survival and immunological parameters in metastatic melanoma patients who responded to ipilimumab 10 mg/kg within an expanded access programme 175
Long-term follow up of metastatic melanoma patients treated with Thymosin alpha-1: investigating immune checkpoints synergy 170
Fourteenth Meeting of the Network Italiano per la Bioterapia dei Tumori (NIBIT) on Cancer Bio-Immunotherapy, Siena, Italy, October 13–15, 2016 138
Clinical experience with ipilimumab 10 mg/kg in patients with melanoma treated at Italian centres as part of a European expanded access programme 122
Targeting cancer vasculature via endoglin/CD105: a novel antibody-based diagnostic and therapeutic strategy in solid tumours 117
Epigenetically regulated clonal heritability of CTA expression profiles in human melanoma 111
CD40 expression by human melanocytic lesions and melanoma cell lines and direct CD40 targeting with the therapeutic anti-CD40 antibody CP-870,893 105
Biology and clinical applications of CD40 in cancer treatment 104
THE ITALIAN EXPERIENCE ON THE FEASIBILITY AND SAFETY OF IPILIMUMAB THERAPY IN PRETREATED METASTATIC MELANOMA PATIENTS 102
Ipilimumab in the common daily practice: feasibility, safety, efficacy and long-term follow-up in heavily pretreated metastatic melanoma patients 101
Ipilmumab in the daily practice: feasibility, safety, efficacy and long term follow-up in heavily pretreated metastatic melanoma patients 95
Clinical Efficacy of the Anti-Cytotoxic T Lymphocyte Antigen-4 (CTLA-4) Monoclonal Antibody Ipilimumab in Pretreated Metastatic Uveal Melanoma Patients 80
Ipilimumab in the common daily practice: Feasibility, safety, and efficacy in heavily pretreated metastatic melanoma patients 79
null 75
Primary hepatic epithelioid hemangioendothelioma progressively responsive to interferon-alpha: is there room for novel anti-angiogenetic treatments? 69
Immune Checkpoint Inhibitors for Cancer Therapy in the COVID-19 Era 65
null 58
Tremelimumab plus durvalumab retreatment and 4-year outcomes in patients with mesothelioma: a follow-up of the open label, non-randomised, phase 2 NIBIT-MESO-1 study 53
Clinical experience with ipilimumab 3 mg/kg: Real-world efficacy and safety data from an expanded access programme cohort 49
Efficacy and safety of an intensified schedule of tremelimumab for chemotherapy-resistant malignant mesothelioma: An open-label, single-arm, phase 2 study 33
Tremelimumab combined with durvalumab in patients with mesothelioma (NIBIT-MESO-1): an open-label, non-randomised, phase 2 study 23
Totale 2.134
Salva come PNG Salva come JPEG
Categoria #
all - tutte 7.560
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 7.560
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020679 0 6 11 78 95 81 123 97 78 68 18 24
2020/2021432 27 30 29 27 46 46 29 66 22 35 12 63
2021/2022212 18 21 20 3 4 11 7 11 13 26 25 53
2022/2023313 20 25 57 25 16 57 13 26 27 18 21 8
2023/2024324 16 4 30 12 4 87 124 6 5 2 17 17
2024/202538 14 24 0 0 0 0 0 0 0 0 0 0
Totale 2.134